HSPA9 and cancer: Through the implementation of the indirect co-immunoprecipitation analyses, Sang-Hyun Park and colleagues had reported a dose-dependent decrease in mortalin fractions that were co-immunoprecipitated with equal amounts of p53 from Az-TPP-O3-treated HeLa cancer cell lysates.